ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-210-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$82.50 million
Profitability
Miscellaneous
Employees66
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The biopharmaceutical company earned $8.98 million during the quarter, compared to analysts' expectations of $11.55 million. ChemoCentryx had a net margin of 13.88% and a return on equity of 32.16%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
6 brokers have issued 1 year target prices for ChemoCentryx's stock. Their predictions range from $12.50 to $20.00. On average, they anticipate ChemoCentryx's share price to reach $17.10 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 3 hold ratings, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/21/2019)
- 2. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year end 2018 net cash of $2.49/ share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (8/13/2018)
Has ChemoCentryx been receiving favorable news coverage?
News stories about CCXI stock have trended very positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR) and Insmed (INSM).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
- Dr. Rajinder Singh, Sr. VP of Research (Age 51)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
- Dr. Markus J. Cappel, Chief Bus. Officer & Treasurer (Age 57)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.26%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Plc Glaxosmithkline, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $11.71.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $591.66 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
